Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment
NCT ID: NCT00932867
Last Updated: 2010-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3114 participants
OBSERVATIONAL
2007-12-31
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Survey to Assess Why People Are Not Responding to Treatment in Hypertension
NCT01071681
Assessment of Compliance With Antihypertensive Telmisartan Therapy
NCT00470886
Ramipril - Hypertension
NCT00325806
Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction
NCT05060588
Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.
NCT00334386
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Kinzal/Pritor (Telmisartan, BAY68-9291)
Patients under daily life treatment receiving Pritor according to local drug information.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Kinzal/Pritor (Telmisartan, BAY68-9291)
Patients under daily life treatment receiving Pritor according to local drug information.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Arterial hypertension (SBP \< 160 mmHg and DBP \< 100 mmHg)
* Patients, who do not tolerate ACE inhibitors (must be documented in the official ambulant documentation)
* Patients over 18 years of age
* Arterial hypertension (SBP \< 160 mmHg and DBP \< 100 mmHg)
* Patients, who tolerate ACEi treatment
Exclusion Criteria
* Allergy to telmisartan
* Gravidity or lactation
* Cholestasis, severe hepatic insufficiency
* Allergy to ACEi
* Gravidity or lactation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bayer spol.s.r.o.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Many Locations, , Romania
Many Location, , Slovakia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14010 - KL0711SK
Identifier Type: -
Identifier Source: secondary_id
14327 - KL0711RO
Identifier Type: -
Identifier Source: secondary_id
14010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.